Lupin rises as its Mandideep Unit-2 Facility completes USFDA inspection with No Observations
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Lupin is currently trading at Rs. 1089.75, up by 12.80 points or 1.19% from its previous closing of Rs. 1076.95 on the BSE.
The scrip opened at Rs. 1077.35 and has touched a high and low of Rs. 1105.80 and Rs. 1077.35 respectively. So far 54151 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1108.95 on 09-Aug-2023 and a 52 week low of Rs. 623.20 on 19-Sep-2022.
Last one week high and low of the scrip stood at Rs. 1108.95 and Rs. 1043.55 respectively. The current market cap of the company is Rs. 49999.14 crore.
The promoters holding in the company stood at 47.07%, while Institutions and Non-Institutions held 43.30% and 9.64% respectively.
Lupin’s Unit-2 manufacturingfacility located in Mandideep, India, has successfully completed a GMP inspection by the United States Food and Drug Administration (USFDA). The inspection was conducted from August 7 to August 11, 2023 and concluded without any observations.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
.jpg)
